Robotic and Laparoscopic Cancer Surgery Explained

This page is for people facing cancer surgery who want to understand laparoscopic and robotic surgery. It covers how they work, what the FDA says, and what trials show for colon, uterine, and cervical cancer.

Open cancer surgery uses one long cut, so the surgeon can look straight into the body and work with gloved hands inside it.

Minimally invasive surgery uses a few small cuts instead. A long, thin tube with a tiny camera goes in through one cut. That tube is a laparoscope. It sends a picture from inside the body to a monitor. Thin tools go in through the other cuts to remove the tumor and a rim of healthy tissue.

In laparoscopic surgery, the surgeon stands at the table and holds those tools by hand.

In robotic-assisted surgery, the surgeon sits at a console a few feet away. The FDA calls these machines RAS devices, short for robotically-assisted surgical devices. The console is the control center. It gives a 3-D view and moves the instruments. A bedside cart holds the camera and three or four hinged arms. A separate cart holds the support gear. That means an electrosurgical unit, which cuts and seals tissue with electric current, plus suction and irrigation pumps and the light source.

The tools themselves are ordinary — scalpels, forceps, graspers, dissectors, scissors, retractors — just mounted on arms.

The FDA is clear that the word "robot" is misleading. The device is not really a robot. It cannot perform surgery without direct human control, so a person is driving it the whole time.

The FDA has cleared RAS devices for laparoscopic work in seven fields: general surgery, heart surgery, colorectal surgery, gynecology, head and neck surgery, chest surgery, and urology. Gallbladder removal, hysterectomy, and prostatectomy are the common jobs. Prostatectomy means removal of the prostate.

Here is the part that surprises people. Those clearances rest on 30 days of patient follow-up. That is a short window. It cannot show whether a cancer comes back.

So the FDA says something sharper. It has not granted marketing authorization for any RAS device in the United States specifically for preventing or treating cancer. Safety judged by cancer outcomes has not been established. Those outcomes are overall survival, recurrence (the cancer coming back), and disease-free survival (living without signs of cancer).

Mastectomy gets its own warning. No RAS device is authorized for removing a breast. The FDA notes the approach differs from the conventional one.

None of that is a ban. The FDA regulates devices, not the practice of medicine. Surgeons may use a cleared device on a person with cancer. It does mean the long-term answer has to come from trials rather than from the clearance paperwork. For three cancers, those trials exist. They do not all say the same thing.

One trial randomly assigned 872 people to laparoscopic-assisted colectomy or open colectomy. It ran as NCCTG-934653, listed as NCT00002575. Median follow-up was 4.4 years.

Recurrence at 3 years was 16% with laparoscopy and 18% with open surgery, and three-year overall survival was 86% and 85%. Cancer coming back in the incision itself was an early worry. It happened in under 1% of both groups. Hospital stay was shorter with laparoscopy (5 days versus 6). NCI says the quality-of-life benefits were minimal and short-term.

That is the pattern people expect. Same cancer result, easier recovery.

The LAP2 trial enrolled 2,616 people with clinical stage I to IIA uterine cancer. It split them 2 to 1. One group had full surgical staging by laparoscopy, the other by open surgery.

Recurrence at 3 years was 11.39% with laparoscopy and 10.24% with open surgery. That is a gap of 1.14 percentage points. Five-year overall survival was 89.8% in both arms. The trial could not formally declare laparoscopy "no worse" (noninferior), but only because both groups recurred less often than the trial had planned for.

Laparoscopy takes longer in the operating room. NCI says it also brought less pain, a shorter stay, and a quicker return to daily activities. The gain at 6 weeks was no longer significant at 6 months. For early uterine cancer, laparoscopy is now favored over open surgery.

Then there is LACC. The full name is the Laparoscopic Approach to Cervical Cancer trial, NCT00614211. It enrolled 631 people. Eligible stages were IA1 with lymphovascular invasion, IA2, and IB1. Eligible cell types were squamous cell, adenocarcinoma, and adenosquamous carcinoma. Of those assigned to minimally invasive radical hysterectomy, 84.4% had laparoscopy. The other 15.6% had robot-assisted surgery.

The trial was built to show the small-cut route was no worse. It showed the opposite.

Disease-free survival at 4.5 years was 86.0% with minimally invasive surgery and 96.5% with open surgery. The hazard ratio for recurrence or death from cervical cancer was 3.74. A hazard ratio compares risk between two groups; 3.74 means the risk was several times higher with minimally invasive surgery. The final analysis came out in 2024. It put 4.5-year disease-free survival at 85.0% versus 96%. Overall survival at 4.5 years was 90.6% versus 96.2%. The hazard ratio for death was 2.71. The authors wrote that an open approach should be the standard of care.

The FDA words this evidence carefully. It notes limited reports of lower long-term survival with the minimally invasive route, laparoscopic or robotic. It also notes other reports finding no significant difference. What is not in dispute is the effect on practice. Radical hysterectomy for early cervical cancer moved back toward an open incision at many centers. Our page on cervical cancer treatment questions covers the rest of that decision.

Operating time was longer with small cuts in the uterine cancer trial. An operation can also start small and be changed to an open incision partway through. Ask your surgeon when that might happen.

Training matters. The FDA does not supervise or accredit surgeon training on these devices. That falls to manufacturers, hospitals, and physicians. Models also differ from each other. The FDA warns that users need training on each specific model.

Most malfunction reports the FDA gets are mundane: component breakage, mechanical problems, image or display trouble. But reports of injuries and deaths do arrive. The agency cautions that such reports can be incomplete or unverified.

The useful conversation is narrow. How many of this exact operation has this surgeon done by each route in the past year? What does the randomized evidence show for this cancer at this stage? Colon, uterine, and cervical give three different answers. What is the plan if the case has to convert to open? Would the number of lymph nodes removed, or the surgical margin, differ by route?

For a wider comparison, see open versus minimally invasive surgery. For the weeks afterward, see recovering from cancer surgery.

• FDA — Computer-Assisted Surgical Systems
• NCI — Surgery to Treat Cancer
• NCI PDQ — Colon Cancer Treatment, health professional version
• NCI PDQ — Endometrial Cancer Treatment, health professional version
• NCI PDQ — Cervical Cancer Treatment, health professional version
• PubMed — LACC trial, first report, PMID 30380365
• PubMed — LACC trial, final overall survival, PMID 38810208